Improvement in visceral fat and glucose metabolism: When mice fed a high-fat diet were administered the GPNMB vaccine, senescent cells were removed from visceral fat, leading to improved chronic inflammation in adipose tissue. This, in turn, has been shown to improve glucose metabolism.
Improvement in atherosclerosis: Administration of the GPNMB vaccine to atherosclerosis model mice resulted in the removal of senescent cells accumulated in atherosclerotic plaques, leading to the amelioration of chronic inflammation. This was observed to shrink the atherosclerotic plaques.
Suppression of frailty progression: Administration of the GPNMB vaccine to aged mice was observed to suppress the progression of frailty. Frailty is an age-related condition characterized by physical decline and diminished function.
Extension of lifespan: Administration of the GPNMB vaccine to a progeria mouse model with Hutchinson-Gilford progeria syndrome demonstrated an extension of lifespan.
Furthermore, GPNMB is specifically expressed in senescent cells and is rarely found in normal cells. This specificity ensures minimal side effects and sustained effectiveness, as confirmed by comparative experiments with existing senolytics.
Dr. Munenori Matsuzawa
Aoyama Medical Clinic
References： 1)Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strainsExp Cell Res. 1961; 25: 585-621. 2)Suda M, et alSenolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice.Nature Aging. 2021; 1: 1117-1126